LEAFCANN
AN EXCITING EARLY STAGE INVESTMENT OPPORTUNITY

The 24th February 2016 was an exciting day for us at LeafCann. The passing of Narcotic Drugs Amendment Bill the Commonwealth Parliament means significant opportunities are opening up for Australian patients and the Australian economy. 

LeafCann is well positioned to respond to the changing regulatory landscape and take advantage of the commercial opportunities that come with being first to market in this new medical cannabis industry. 

Our expert team has ensured that LeafCann’s regulatory affairs, quality assurance, security planning and overall business strategy are all in place. 

Now we’re looking forward to moving ahead with the next stage of becoming a leading industry brand, thought leader and innovator. There’s never been a better time to invest in alternative medicine. 


GLOBAL MARKET OPPORTUNITIES FOR MEDICAL CANNABIS (MC)

Cannabinoids legal in 23 US states: the MC market estimated to be worth US$2.7B globally in 2014, reaching US$10B by 2019.  

Cannabinoids legal in 23 US states: the MC market estimated to be worth US$2.7B globally in 2014, reaching US$10B by 2019.  

In Canada the MC market expected to grow from US$144M in 2014 to US$1.3B in 2024. 

In Canada the MC market expected to grow from US$144M in 2014 to US$1.3B in 2024. 

In Europe MC imports estimated to reach US$10M by 2018.

In Europe MC imports estimated to reach US$10M by 2018.

Common diseases for which Cannabinoids have shown high levels of efficacy have a combined sales of +US$300M. 

Common diseases for which Cannabinoids have shown high levels of efficacy have a combined sales of +US$300M. 

Extensive scientific research underway, with 309 of 606 WIPO cannabis-related patents filed by Chinese companies. Cannabis a legal commodity in Uruguay, North Korea and some Indian states. 

Extensive scientific research underway, with 309 of 606 WIPO cannabis-related patents filed by Chinese companies. Cannabis a legal commodity in Uruguay, North Korea and some Indian states.